Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 12/2018

29.10.2018 | Adis Drug Evaluation

Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster

verfasst von: Yahiya Y. Syed

Erschienen in: Drugs & Aging | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years. In the pivotal trials in adults aged ≥ 50 years (ZOE-50) and ≥ 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged ≥ 70 years. In patients with breakthrough disease, RZV reduced HZ-related pain severity, burden of illness and burden of interference with activities of daily living. RZV was more reactogenic than placebo, with injection-site reactions, myalgia and fatigue being the most common solicited adverse reactions. However, most solicited adverse reactions were transient and were mild to moderate in severity. RZV represents a novel, highly effective and well-tolerated vaccine option for HZ and PHN in adults aged ≥ 50 years. RZV is not contraindicated in immunocompromised individuals, and is preferred over a live attenuated HZ vaccine in immunocompetent individuals, according to the US and Canadian guidelines.
Literatur
1.
Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369(3):255–63.CrossRef
2.
3.
Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109–20.CrossRef
4.
Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.CrossRef
5.
6.
7.
Keating GM. Shingles (herpes zoster) vaccine (Zostavax®): a review in the prevention of herpes zoster and postherpetic neuralgia. BioDrugs. 2016;30(3):243–54.CrossRef
8.
Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2016;3:CD008858.PubMed
9.
10.
Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–34.CrossRef
11.
Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccines Immunother. 2017;13(8):1789–97.CrossRef
12.
Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920–30.CrossRef
13.
Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30(20):3126–35.CrossRef
14.
Cunningham AL, Heineman TC, Lal H, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–60.CrossRef
15.
Strezova A, Godeaux O, Aggarwal N, et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine. 2017;35(48 Pt B):6700–6.CrossRef
16.
Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148–54.CrossRef
17.
Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–61.CrossRef
18.
Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343–51.CrossRef
19.
Godeaux O, Kovac M, Shu D, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum Vaccines Immunother. 2017;13(5):1051–8.CrossRef
20.
Vink P, Shiramoto M, Ogawa M, et al. Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs. intramuscularly. Hum Vaccines Immunother. 2017;13(3):574–8.CrossRef
21.
Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–53.CrossRef
22.
Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. J Infect Dis. 2013;208(12):1953–61.CrossRef
23.
Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults. Hum Vaccines Immunother. 2013;9(7):1425–9.CrossRef
24.
Marechal C, Lal H, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥ 50 years of age: a randomized trial. Vaccine. 2018;36(29):4278–86.CrossRef
25.
Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206(8):1280–90.CrossRef
26.
Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–8.CrossRef
27.
Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccines Immunother. 2018;14(6):1370–7.CrossRef
28.
Diez-Domingo J, Kovac M, Vesikari T, et al. Efficacy and immunogenicity of an investigational subunit adjuvanted herpes zoster vaccine in older adults in Europe: results from the ZOE-50 and ZOE-70 efficacy studies [abstract no. P543]. Eur Geriatr Med. 2016;7(Suppl. 1):S172.
29.
30.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRef
31.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.CrossRef
32.
Curran D, Van Oorschot D, Varghese L, et al. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccines Immunother. 2017;13(10):2213–21.CrossRef
33.
Kovac M, Lal H, Cunningham AL, et al. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537–41.CrossRef
34.
35.
Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. Am J Transplant. 2018;18(3):756–62.CrossRef
36.
Esposito S, Bonanni P, Maggi S, et al. Recommended immunization schedules for adults: clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccines Immunother. 2016;12(7):1777–94.
37.
38.
Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.CrossRef
39.
40.
Oostvogels L, Zoster-039 Study Group. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial [abstract no. 1344 plus poster]. In: IDWeek 2017.
41.
Vink P, Zoster-039 Study Group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II/III, randomized clinical trial [abstract no. 1349 plus poster]. In: IDWeek 2017.
42.
Vink P, Zoster-041 Study group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (HZ/su) in adults post renal transplant: a phase III randomized clinical trial [abstract no. 1348 plus poster]. In: IDWeek 2017.
43.
Sullivan K, Abhyankar S, Campora L, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in adult autologous hematopoietic stem cell transplant recipients: phase 3, randomized, placebo-controlled, ZOE-HSCT clinical trial [abstract]. In: 44th annual meeting of the European Society for Blood and Marrow Transplantation. 2018.
44.
Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87.CrossRef
45.
Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–9.CrossRef
46.
Burnett H, McGirr A, Widenmaier R, et al. Vaccines for herpes zoster: a systematic review of randomized controlled trials in adults ≥ 50 years of age [abstract no. PIN12 and poster]. Value Health. 2017;20(9):A780.CrossRef
47.
Gabutti G, Bonanni P, Conversano M, et al. Prevention of herpes zoster and its complications: from clinical evidence to real life experience. Hum Vaccines Immunother. 2017;13(2):391–8.CrossRef
48.
de la Serna J, Campora L, Chandrasekar P, et al. Efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18 years of age or older: first results of the phase 3 randomized, placebo-controlled ZOE-HSCT clinical trial [abstract]. In: 2018 blood and marrow transplantation tandem meetings.
49.
Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45.CrossRef
50.
51.
Van Oorschot DA, Loiacono I, Pitrelli A, et al. Forecasting the potential public health impact of herpes zoster vaccination in Italy [abstract no. PIH4]. Value Health. 2017;20(9):A520.CrossRef
52.
Van Oorschot DA, Hunjan M, Varghese L, et al. The public health perspective of an investigational herpes zoster vaccine in the United Kingdom (UK) [abstract no. PIH5 and poster]. Value Health. 2016;19(7):A400.
Metadaten
Titel
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
verfasst von
Yahiya Y. Syed
Publikationsdatum
29.10.2018
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 12/2018
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0603-x

Weitere Artikel der Ausgabe 12/2018

Drugs & Aging 12/2018 Zur Ausgabe

Original Research Article

Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation

Letter to the Editor

Authors’ Reply to Stefani: “Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)”

Letter to the Editor

Comment on: “Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)”

Short Communication

Efficacy of a Standardized Oral Vitamin D Dosing Regimen in Nursing Home Residents

Review Article

Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns

Original Research Article

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise